AstraZeneca Lynparza Trial Results 'Unprecedented'
June 03 2019 - 2:48AM
Dow Jones News
By Oliver Griffin
AstraZeneca PLC (AZN.LN) on Monday said phase 3 results from a
trial of its Lynparza cancer treatment, developed with Merck &
Co. Inc. (MRK), demonstrated that the drug nearly doubled the time
patients lived without disease progression.
The British pharmaceutical company said the POLO trial of
Lynparza for patients with pancreatic cancer showed that 22% of
remained free of disease progression after two years, compared with
just 10% on a placebo.
AstraZeneca said Lynparza is now the first PARP inhibitor--a key
type of cancer treatment--to demonstrate benefit in three different
cancer types.
Jose Baselga, the company's executive vice president of oncology
research and development, said the "unprecedented results" raise
new hope for patients that have seen little progress over a long
time.
Separately, AstraZeneca said that results from the phase 3
Pacific trial of Imfinzi, a treatment used to treat non-small cell
lung cancer, ended with 57% of patients alive at three years,
compared with 43.5% receiving the placebo.
Write to Oliver Griffin at oliver.griffin@dowjones.com;
@OliGGriffin
(END) Dow Jones Newswires
June 03, 2019 02:33 ET (06:33 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
From Apr 2024 to May 2024
Merck (NYSE:MRK)
Historical Stock Chart
From May 2023 to May 2024